Fingolimod effect on brain volume loss independently contributes to its effect on disability

Abstract

Background:

Brain volume loss occurs in patients with relapsing–remitting MS. Fingolimod reduced brain volume loss in three phase 3 studies.

Objective:

To evaluate whether the effect of fingolimod on disability progression was mediated by its effects on MRI lesions, relapses or brain volume loss, and the extent of this effect.

Methods:

Patients (992/1272; 78%) from the FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study were analyzed. Month-24 percentage brain volume change, month-12 MRI-active lesions and relapse were assessed. The Prentice criteria were used to test surrogate marker validity. The proportion of treatment effect on disability progression explained by each marker was calculated.

Results:

Two-year disability progression was associated with active T2 lesions (OR = 1.24; p = 0.001) and more relapses during year 1 (OR = 2.90; p < 0.001) and lower percentage brain volume change over two years (OR = 0.78; p < 0.001). Treatment effect on active T2 lesions, relapses and percentage brain volume change explained 46%, 60% and 23% of the fingolimod effect on disability. Multivariate analysis showed the number of relapses during year 1 (OR = 2.62; p < 0.001) and yearly percentage brain volume change over two years (OR = 0.85; p = 0.009) were independent predictors of disability progression, together explaining 73% of fingolimod effect on disability.

Conclusions:

The treatment effect on relapses and, to a lesser extent, brain volume loss were both predictors of treatment effect on disability; combining these predictors better explained the effect on disability than either factor alone.

Keywords

Brain volume loss fingolimod multiple sclerosis MRI relapse surrogate markers

Get full access to this article

View all access options for this article.

References

De Stefano

Giorgio

Battaglini

. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868–1876.

Fisher

Lee

Nakamura

. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 2008; 640: 255–265.

Giorgio

Battaglini

Smith

. Brain atrophy assessment in multiple sclerosis: Importance and limitations. Neuroimaging Clin N Am 2008; 18: 675–686.

De Stefano

Airas

Grigoriadis

. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28: 147–156.

Sormani

Arnold

De Stefano

. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2013; 75: 43–49.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Calabresi

Radue

Goodin

. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545–556.

Brinkmann

. FTY720 (fingolimod) in multiple sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173–1182.

10.

Smith

De Stefano

Jenkinson

. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466–475.

11.

Panitch

Goodin

Francis

. Randomized, comparative study of interferon β-1a treatment regimens in MS: The evidence trial. Neurology 2002; 59: 1496–1506.

12.

Prentice

. Surrogate endpoints in clinical trials: Definition and operational criteria. StatMed 1989; 8: 431–440.

13.

Sormani

Bruzzi

Miller

. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: Implications for clinical trials. J Neurol Sci 1999; 163: 74–80.

14.

Lin

Fleming

Gruttola

. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997; 16: 1515–1527.

15.

Simon

. Brain atrophy in multiple sclerosis: What we know and would like to know. Mult Scler 2006; 12: 679–687.

16.

Barkhof

Calabresi

Miller

. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256–267.

17.

Fotenos

Mintun

Synder

. Evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 2008; 65: 113–120.

18.

Filippi

Bozaali

Rovaris

. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433–437.

19.

Bermel

Bakshi

. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5: 158–170.

20.

Calabrese

Agosta

Rinaldi

. Cortical lesions and atrophy associated with cognitive impairment in relapsing–remitting multiple sclerosis. Arch Neurol 2009; 66: 1144–1150.

21.

Prinster

Quarantelli

Orefice

. A voxel-based morphometry study of disease severity correlates in relapsing–remitting multiple sclerosis. Mult Scler 2010; 16: 45–54.

22.

Minneboo

Jasperse

Barkhof

. Predicting short-term disability progression in early multiple sclerosis: Added value of MRI parameters. J Neurol Neurosurg Psychiatry 2008; 79: 917–923.

23.

Sormani

Bonzano

Roccatagliata

. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65: 268–275

24.

Sormani

Bruzzi

. MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomized trials. Lancet Neurol 2013; 12: 669–676.

25.

Sormani

Bonzano

Roccatagliata

. Surrogate end-points for EDSS worsening in multiple sclerosis: A meta-analytic approach. Neurology 2010; 5: 256–266.

26.

Sormani

Stubinski

Cornelisse

. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 2011; 17: 541–549.

27.

Sormani

Bruzzi

. Combined MRI lesion and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011; 77: 1684–1690.

28.

Radue

Barkhof

Kappos

. (In Press). Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 2015 Jan 28. pii: 10.1212/WNL.0000000000001281. [Epub ahead of print].

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB